Regenxbio shares details from its earnings call for the second quarter of 2026.

Oct 5, 2026, 7:03 AM ETResultsRead the original at Benzinga

Good for RGNX

Regenxbio completed enrollment in an important study and received a $100 million payment from AbbVie, strengthening its cash position. Its planned FDA filing and product launches are still ahead, but the added funding and study progress support a stronger outlook.

RGNX · Regenxbio

AI read · Good for RGNX

The AI's read

The completed study enrollment and AbbVie payment give Regenxbio more support to prepare its programs and planned launch. The company also says its cash should last through the expected FDA decision for RGX202. The FDA filing and any product sales are still ahead, so success is not assured.

Get alerts for RGNX

Follow Regenxbio (RGNX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RGNX

Free on the App Store and Google Play, or on the web.